Clofutriben
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Clofutriben
- Molecular weight
- 424.81
- Structure (SMILES)
- Cn1c(-c2ccc(C(N)=O)cc2F)nnc1C(C)(C)Oc1c(F)cc(Cl)cc1F
- 12mg clofutriben
- as 2473662
- AS-2473662
- as2473662
- AS2473662
- asp 3662
- ASP-3662
- asp3662
- Asp3662
- ASP3662
- clofutriben
- Clofutriben
- clofutriben [INN]
- CLOFUTRIBEN [USAN]
- Clofutriben [WHO-DD]
- clofutriben inn
- clofutriben usan
- clofutriben who dd
- clofutribene
- Clofutribene
- hdd 1697
- HDD-1697
- spi 62
- Spi-62
- SPI-62
- CAS registry numbers
- 1204178-50-6
- ChEMBL ID
- CHEMBL5314513
- InChIKey
- CMQOKZCYVZFZLZ-UHFFFAOYSA-N
- PubChem compound IDs
- 44598960
- FDA ingredient codes (UNII)
- 4L1TY1U5VC
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Condition
- Polymyalgia Rheumatica
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008518
- Subject identifier
- D011111
- Condition
- Diabetic Neuropathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000783
- Subject identifier
- D003929
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006640
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018912
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019735
- Highest recorded phase
- 2
- NCT02372578
- NCT05436652
- NCT06281236
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 83.03
- Calculated partition coefficient (ALogP)
- 3.97
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 29
- Molecular formula
- C19H16ClF3N4O2
- Monoisotopic mass
- 424.0913879
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (10)
- A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
- A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
- A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
- A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)
- Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
- Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone
- SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
- SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
- Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
In development for (3)
- Alzheimer disease Phase 1
- Diabetic neuropathy Phase 2
- Polymyalgia rheumatica Phase 2